X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Apabetalone (RVX000222), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease progression.
Lead Product(s): Apabetalone,Atorvastatin,Rosuvastatin
Therapeutic Area: Endocrinology Product Name: RVX000222
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
Apabetalone (RVX-208/RVX000222), is first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action, is selective BET inhibitor that works in preventing and treating disease progression by regulating the expression of disease-causing genes.
Lead Product(s): Apabetalone
Therapeutic Area: Cardiology/Vascular Diseases Product Name: RVX000222
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
RVX-208 (apabetalone), is first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 selective BET inhibitor that works in preventing and treating disease progression by regulating expression of disease-causing genes.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
Apabetalone’s unique dual epigenetic mechanism may help stop disease progression by regulating the expression of disease and inflammation causing genes, without altering DNA.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2022
Details:
The Supreme Council of the Arab-African Economy is pleased to be in collaboration with Resverlogix to provide the necessary investment and assistance to support the emergence of apabetalone (RVX-208) into the Arab-African Economy.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Supreme Council of the Arab-African Economy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 03, 2021
Details:
Apabetalone (RVX-208), a first-in-class, epigenetic small molecule, or gene regulating, therapeutic candidate. It is a selective BET (bromodomain and extra-terminal) inhibitor, which works in preventing disease by turning genes on and off through regulation of gene expression.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
Details:
Apabetalone (RVX-208), is a first-in-class, epigenetic small molecule, or gene regulating, therapeutic candidate. It is a selective BET inhibitor, which works in preventing disease by turning genes on and/or off through regulation of gene expression.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Details:
Apabetalone inhibits SARS-CoV-2 infection in vitro to levels comparable to those of antiviral agents. The study supports further evaluation of apabetalone to treat COVID-19, either alone or in combination with emerging therapeutics.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2021
Details:
The planned Phase 2 trial will be an open-label study evaluating the safety and efficacy of oral apabetalone, in combination with standard of care for patients hospitalized with COVID-19.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
Details:
In BETonMACE study, significantly fewer hospitalizations for heart failure (HHF) in patients with type 2 diabetes and a recent history of acute coronary syndrome (ACS) were observed in the apabetalone treatment group compared to placebo.
Lead Product(s): Apabetalone
Therapeutic Area: Cardiology/Vascular Diseases Product Name: RVX-208
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2021
Details:
Apabetalone was shown to inhibit expression of Angiotensin-converting enzyme 2 (ACE2), the receptor utilized by the novel coronavirus to enter human cells.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
The FDA has accepted Resverlogix BETonMACE2 clinical plan as a registration enabling study with positive implications for Resverlogix and its ongoing partnership discussions.
Lead Product(s): Apabetalone,Atorvastatin
Therapeutic Area: Endocrinology Product Name: RVX000222
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
For the first time in patients with a recent Acute Coronary Syndrome with diabetes and stage 3 CKD co-morbidities, we observed a 50% reduction of MACE by a medication, apabetalone treatment.
Lead Product(s): Apabetalone,Atorvastatin
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Details:
An additional step will be to proceed with an open-label study to assess the safety and efficacy of a clinical course of oral apabetalone in hospitalized subjects with 2019-nCoV infection on top of standard of care compared to standard of care alone.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
Apabetalone recently completed the first ever Phase 3 clinical trial of a BET inhibitor for a cardiovascular disease indication.
Lead Product(s): Apabetalone,Atorvastatin
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2020
Details:
The study demonstrates apabetalone to inhibit specialized proteins called bromodomain and extraterminal domain proteins from interacting with a SARS-CoV-2 viral protein.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2020
Details:
Resverlogix is seeking to collaborate with organizations currently testing therapies for SARS-CoV-2 in pre-clinical or clinical models.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 23, 2020
Details:
FDA has granted Breakthrough Therapy Designation for apabetalone in combination with high-intensity statins, for the secondary prevention of MACE in patients with type 2 DM and recent ACS.
Lead Product(s): Apabetalone
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2020
Details:
BETonMACEresults show 57% hazard reduction in primary mace for patients on apabetalone and new oral anti-diabetic treatments.
Lead Product(s): Apabetalone
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
